1 active not recruiting, 1 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow F 4: new trials by email Literature Review of F 4 trials Research Report on F 4
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007) MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4) - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 48 | 2026-08-25 | 2026-09-23 |
| Phase 1, Febuxostat XR Relative Bioavailability Study Febuxostat XR 80 mg Capsule F1, Febuxostat XR 80 mg Capsule F2, Febuxostat XR 80 mg Capsule F3 - Healthy Volunteers | Phase 1 | Completed | Takeda | 78 | 2015-08-01 | 2017-01-19 |
Merck Sharp & Dohme LLC (1) · Takeda (1)
United States (2)